Norsa Pharmasp. z o.o.

Manufacture of food supplements

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2015-01-26
Share capital
7 500,00 PLN
Activity description

Norsa Pharma is a Polish manufacturer that offers a wide range of specialized dietary supplements tailored to various health needs. Their product lineup includes items such as Omegasense Gold, Creatine Nucleo, and Vitamin D3+K2, among others. The company focuses on nutritional preparations to support health and well-being.

Registered address
ul. Prof. Michała Życzkowskiego 14, 31-864 Kraków, Poland
Website
norsapharma.euWebsite active
Email
Email address current
Social media

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 9.11mMedianUSD 405.61kAverageUSD 8.05m
Net profit
This companyUSD 3.02mMedianUSD 4.82kAverageUSD 675.08k
Operating costs
This companyUSD 5.32mMedianUSD 406.14kAverageUSD 7.09m
Assets
This companyUSD 4.33mMedianUSD 362.60kAverageUSD 7.78m

Bank accounts

Registered as a VAT taxpayer on 2015-02-13. Active

  • mBank
    27 1140 1049 0000 2773 4800 1003
  • mBank
    54 1140 1049 0000 2773 4800 1002
  • mBank
    81 1140 1049 0000 2773 4800 1001

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

8 public aid cases recorded, with a total value of $708,549.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,596
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,670
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,670

European Funds

ProjectEU co-financing
Kompleksowe opcje terapii niedoborów z˙ywieniowych w mukowiscydozie: biodoste?pnos´c´, skutecznos´c´, redukcja kosztów.
$449.8K

Tenders

No recorded participation in tenders.

Trademarks

Norsa Pharma holds 23 active trademarks registered with the Polish Patent Office. 1 application is pending. 6 marks have expired or were not registered. The first mark was filed in 2015.

MarkProtected until
iONA+(word)Apr 27, 2036
Duofibrin(word)Feb 12, 2036
NORDIGAST(word)Dec 3, 2035
CreatineNucleo(word)Aug 13, 2035
Omegasense(word)Jun 26, 2035

Authorized Representatives

Mateusz Łukasz Data – President of the Management Board

Manner of representation

In the case of a one-person management board, the sole member of the management board is authorised to make declarations of will on behalf of the company. In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board together with a commercial proxy is required.

Ownership

OwnerSharesShare valueStake
Mateusz Łukasz Data (43)
33$891.4144%
Marta Kowal (43)
17$459.2122.6667%
12$324.1516%
Jarosław Mirosław Walkowiak (59)
8$216.1010.6667%
Others
5$135.066.6666%

Beneficial owners

Person

Competitors

Name
Global Pharma CmS.A.
Master PharmS.A.
ALG Pharmasp. z o.o.
Laboratoria Naturysp. z o.o.
Premium Rosasp. z o.o.
Yangosp. z o.o.
Supplelabsp. z o.o. + limited partnership
Chias Brothers Europesp. z o.o.
Noble Healthsp. z o.o.
OnesanoS.A.

Change history

DateEvent
2025-06-20PKD change
2020-02-20Share capital change
2019-11-27Share capital change
2018-06-11Address change
2018-06-11Share capital change

FAQ

Last updated: 2026-05-19